In short
- Fifty-two people with metastatic cancer and anxiety or depression took part in a three-day group retreat with one 25 mg psilocybin session.
- There were no unattended episodes of distress and no serious adverse events on the dosing day.
- Twenty-eight days later, anxiety and depression scores had fallen and demoralisation and quality of life had improved.
What the researchers did
Researchers in the USA ran eight retreats with a fixed team of facilitators, slowly increasing the group from five to eight participants as they learned what was safe. Participants had cancer that could no longer be cured, and most were still receiving cancer treatment. The main question was practical: can one team care for a small group in the same session without anyone being left alone in distress?
What they found
Nobody needed a backup facilitator for unattended distress in any session. Every participant said they had received enough attention and that the others in the group had been well supported. Side effects were mild and short-lived, such as nausea or malaise.
Anxiety and depression scores dropped between the start and 28 days after dosing, and participants reported less demoralisation and better quality of life. The authors suggest the group format may offer an experience as deep as individual sessions.
Why it matters
At the end of life the questions the Numinous Way cares about become most urgent: meaning, connection and facing death. Many people imagine psychedelic therapy as something done alone with one therapist. This study suggests that a group, carefully held, can be safe and supportive, and may add something of its own: the experience of not being alone. That is close to what we see in our own small-group retreats.
Keep in mind
There was no control group, so the improvements cannot be put down to psilocybin alone, and the efficacy results were exploratory. Participants were carefully screened and supported; the findings do not apply to unsupervised use.
Not sure where to start?
Book a free 30-minute call with one of our practitioners and ask your questions, with no obligation.
Book a free callThis summary is for information only and is not medical advice. Psychedelics are controlled substances in many countries, including the UK.
You may also like
Feeling Connected: The Key to Lasting Benefits After a Retreat?
Following 173 guests of guided psilocybin retreats in the Netherlands for a year, researchers found lasting wellbeing gains, linked above all to connectedness.
Danielle Tanner · 30 October 2026
ResearchWhen Nothing Feels Good: Can Psilocybin Help Bring Back Joy?
A small trial tested psilocybin with psychological support for anhedonia, the loss of pleasure, in treatment-resistant depression. The results were mixed but hopeful.
Monika Knitter · 6 November 2026
ResearchSetting Matters: Music, Meditation and the Brain on Psilocybin
The largest EEG study of psilocybin so far found that music, meditation and film each reshaped the brain’s response compared with simple rest.
Monika Knitter · 23 October 2026
